Myriad Genetics, Inc. (MYGN) financial statements and ratios from SEC XBRL: revenue $0.8B (TTM), net margin -44.4%, revenue growth -10.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $824.50M |
| Revenue (TTM) | $0.8B |
| Net Margin | -44.4% |
| Operating Margin (TTM) | -12.2% |
| Net Debt / EBITDA | -0.1 |
| Revenue Growth (YoY) | -10.5% |
| EPS Growth (YoY) | -87.1% |
| Price / Book | 1.02 |
| Price / Sales | 0.38 |
| Altman Z-Score | -2.00 (distress) |
| Piotroski F-Score | 5/9 |
| Piotroski checks passed | 5 of 9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
MYGN overview · MYGN earnings · MYGN KPIs · MYGN documents · MYGN ownership · MYGN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.